San Diego-based medical device company ResMed has announced the acquisition of mementor, a consumer software developer that provides digital solutions for insomnia.
The financial terms of the transaction were not disclosed.
The company says its acquisition of Germany-based Leipzig lays the groundwork for ResMed to build out its digital sleeping pill portfolio in Germany. The deal was finalized on August 1.
Mementor will be integrated into ResMed in Germany as a separate business and will serve as a platform for further developments in the field of digital health. Through the acquisition, the mementor can leverage ResMed Germany’s broader network to increase adoption of its digital health app, somnio.
The business segment will be led by co-founder and CEO of mementor, Dr. Noah Lorenz and Katherina Jekerle, who was previously ResMed Germany’s Senior Marketing Manager and a member of the German leadership team.
WHY IS THIS PROBLEM?
Mementor has developed the digital health app somnio, which focuses on improving sleep in patients diagnosed with insomnia. Somnio fills the care gap by providing an alternative to prevailing drug therapy.
ResMed says somnio complements its efforts to raise awareness about insomnia and sleep apnea, and provides users with effective home treatments.
Somnio is available in Germany through a “prescription app.”
Somnio is Germany’s first and only permanently approved digital health app in the field of sleep medicine, according to ResMed. This makes it eligible for a refund in Germany.
The clinical effectiveness of somnio has been demonstrated in two randomized controlled trials, showing sustained improvement in users’ sleep after two and 12 months, according to ResMed.
TREND TO BIGGER WOMAN
Founded in Switzerland in 2014 by Dr. Noah Lorenz, Alexander Rötger, Jan Kühni and Daniel Rotzetter, mementor has developed and owns the digital insomnia therapy solution somnio.
It is the first and only German Digital Health Application (DiGA) permanently approved in the field of sleep medicine and also complies with the data protection requirements of the European Union under Regulation General Data Protection.
In Germany, about 1 in 10 people are affected by clinically relevant insomnia, as are almost 3 in 10 people with sleep apnea.
Currently, only a small percentage of those affected receive cognitive behavioral therapy for insomnia (CBT-I) recommended in the German S3 guideline, according to ResMed.
ResMed offers outpatient software programs to assist people with sleep apnea, COPD, and other chronic conditions.
In June, ResMed signed a definitive agreement to acquire Medifox Dana German out-of-hospital software company, from software investor Hg for $1 billion (€950 million).
Katrin Pucknat, president of ResMed Germany, said, “The founders have identified a large and neglected area of healthy sleep with the opportunity to help millions of people solve their chronic sleep problems. with an easy-to-use home digital solution. We look forward to working with the team at mementor to help more people in Germany get a good night’s sleep. “
Email the writer: SMorse@himss.org